Video
Chip Petricoin on the Discovery of New Biomarkers
Author(s):
Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.
Emanuel F. “Chip” Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.
There have been many large, publicly-funded biomarker discovery efforts, Petricoin says. The National Cancer Institute (NCI) has increase its effort to more methodically develop, discover, evaluate, and validate biomarkers. The process has been supported by the fact that many of these biomarkers have been approved by the FDA.
The NCI has also developed biomarkers that have translated well from the clinical to commercial setting in imaging, high-risk population screening, and recurrence monitoring.
